Neuroinflammation in Hypertension Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-02

Study Completion Date

2025-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate that in patients with resistant hypertension oral treatment with minocycline via inhibition of central immune cell activation and inflammation results in reduced central sympathetic outflow and concomitant lowering of BP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

NCT02133872

Hypertension

COMPLETED PHASE2

Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

NCT02133885

Hypertension

WITHDRAWN PHASE1/PHASE2

Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health

NCT02972619

Hypertension Cardiovascular Disease

UNKNOWN NA

Use of Angiotensin-(1-7) in COVID-19

NCT04633772

Infection, Coronavirus Respiratory Failure

COMPLETED PHASE1/PHASE2

Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives

NCT04357535

COVID-19

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, placebo controlled, parallel group design study aiming to compare the effects of minocycline 100mg twice daily vs matched placebo for 12 weeks on ambulatory BP and the parameters of sympathetic and immune activation

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Resistant Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Minocycline Group

Subjects will be randomized to receive Minocycline 100mg twice daily

Group Type ACTIVE_COMPARATOR

Minocycline

Intervention Type DRUG

Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.

Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase.

Placebo Group

Subjects will be randomized to receive placebo.

Group Type PLACEBO_COMPARATOR

Minocycline

Intervention Type DRUG

Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.

Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Minocycline

Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.

Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Akamin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged: 45 -65 years
* Signed informed consent
* Clinical diagnosis of Resistant Hypertension
* Daytime systolic ambulatory BP \>135mmHg.

Exclusion Criteria

* History of myocardial infarction (MI) or any cardiovascular event within 3 months of screening period, clinically significant AV conduction disturbances and/or arrhythmias,
* current of past history of heart failure (LVEF ≤40%)
* psychotropic agents, antidepressants and NSAIDS
* alcohol consumption of \>3 standard drinks.
* known hypersensitivity or contraindication to minocycline or other tetracyclines.

Minimum Eligible Age

45 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No